Cancer immunotherapy based on the killing of Salmonella typhimurium-infected tumour cells

Bibliography

• COLEY WB: The treatment of malignant tumours by repeated inoculations of erysipelas; with a report of ten original cases. Am. J. Med. Set. (1893) 105:487–511.
   Google Scholar
• CHEADLE EJ, JACKSON AM: Bugs as drugs for cancer. Immunology (2002) 107:10–19.
   PubMed Web of Science ®Google Scholar
• PAWALEK JM, LOW KB, BERMUDES D:Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. (1997) 57:4537–4544.
   PubMed Web of Science ®Google Scholar
• DUNLAP NE, BENJAMIN WH JR, MCCALL RD JR, TILDEN AB, BRILES DE: A safe-site of Salmonella typhimurium is within splenic cells during early pase of infection in mice. Microb. Pathog-. (1991) 10:297–310.
   PubMed Web of Science ®Google Scholar
• MEDINA E, GUZMAN CA, STAENDNER LH, CLOMBO MP, PAGLIA P: Salmonella vaccine carrier strains: effective delivery system to trigger anti-tumor immunity by oral route. Eur. ImmunoL (1999) 29:693–699.
   PubMed Web of Science ®Google Scholar
• MASTROENI P, MENAGER N: Development of acquired immunity to Salmonella. J. Med. Microbiol. (2003) 52:453–459.
   PubMed Web of Science ®Google Scholar
• SIRARD JC, NIEDERGANG F, KRAEHENBUHL JP: Live attenuated Salmonella: a paradigm of mucosal vaccines. ImmunoL Rev. (1999) 171:5–26.
   PubMedGoogle Scholar
• HONE DM, ATTRIDGE SR, FORREST B et al.: A gale via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. (1988) 56:1326–1333.
   PubMed Web of Science ®Google Scholar
• CURTISS R 3'1, KELLY SM: Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun. (1987) 55:3035–3043.
   PubMed Web of Science ®Google Scholar
• GALAN JE, CURTISS R 311: Cloning and molecular characterization of genes whose products allow Salmonella typhimurium to penetrate tissue culture cells. Proc. NatL Acad. St-Z. USA (1989) 86:6383–6387.
   PubMed Web of Science ®Google Scholar
• KELLY SM, BOSECKER BA, CURTISS RD 3'1: Characterization and protective properties of attenuated mutants of Salmonella choleraesuis. Infect. Immun. (1992) 60:4881–4890.
   PubMed Web of Science ®Google Scholar
• TACKET CO, HONE DM, CURTISS RD 3'1 et al.: Comparison of the safety and immunogenecity of EaroC EaroD, and Ecya Ecrp Salmonella typhi strains in adult volunteers. Infect. Immun. (1992) 60:536–541.
   Google Scholar
• KING I, BERMUDES D, UN S et al.: Tumor targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum. Gene Ther. (2002) 13:1225–1233.
   PubMed Web of Science ®Google Scholar
• GUO CC, DING J, PAN BR et aL: Development of an oral DNA vaccine against MG7-an of gastric cancer using attenuated Salmonella typhimurium as a carrier. World J. GastroenteroL (2003) 9(0:1191–1195.
   PubMedGoogle Scholar
• SALTZMAN DA, HEISE CP, HASZ DE et al.: Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother. Radiopharm. (1996) 11(2):145–153.
   PubMed Web of Science ®Google Scholar
• SALTZMAN DA. KATSANIS E, HEISE CP et al.: Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? Pediatr. Surg (1997) 32(2):301–306.
   Google Scholar
• SALTZMAN DA, KATSANIS E, HEISE CP et al.: Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent. Cancer Biother. Radiopharm. (1997) 12(1):37–45.
   PubMed Web of Science ®Google Scholar
• FELTIS BA, MILLER JS, SAHAR DA et ell.: Liver and circulating NK1.1(+)CD3(-) cells are increased in infection with attenuated Salmonella typhimurium and are associated with reduced tumor in murine liver cancer. Surg-. Res. (2002)107:101–107.
   Google Scholar
• FELTIS BA, SAHR DA, KIM AS, SALTZMAN DA, LEONARD AS, SIELAFF TD: Cyclooxygenase 2 inhibition augments hepatic antitumor effect of oral Salmonella typhimurium in a model of mouse metastatic colon cancer. Dis. Colon Rectum (2002) 45(8):1023–1028.
   PubMed Web of Science ®Google Scholar
• SOTO LJ, SORENSON BS, KIM AS, FELTIS BA, LEONARD AS, SALTZMAN DA: Attenuated Salmonella typhimurium prevents the establishment of hepatic colorectal metastases and improves survival in a murine model. Tumor Biol. (2002) 23\(Suppl. 1):30.
   Google Scholar
• SOTO LJ, SORENSON BS, NELSON BW, BARNETT SJ, LEONARD AS, SALTZMAN DA: A kinetic analysis of the cytotoxic response to immunotherapy with Salmonella typhimurium in a hepatic metastases model. (2005) (In Press).
   Google Scholar
• SOTO LJ, SORENSON BS, NELSON B, SOLIS S, LEONARD AS, SALTZMAN DA: Preferential proliferation of attenuated Salmonella typhimurium within neuroblastoma. j Pediatr. Surg-. (2004) 39(0:937–940.
   PubMedGoogle Scholar
• SOTO LJ, SORENSON BS, NELSON BW, LEONARD AS, SALTZMAN DA: Generation of immunity to hepatic metastases by attenuated Salmonella typhimurium. Ann. Surg-. Oncol (2004) 11(2 Suppl.):5107.
   Google Scholar
• SMITH KA: Lowest dose interleukin-2 immunotherapy. Blood (1993) 81(6):1414–1423.
   PubMed Web of Science ®Google Scholar
• KINTZEL PE, CALIS KA: Recombinant interleukin-2: a biological response modifier. Clin. Pharm. (1991) 10:110–128.
   PubMedGoogle Scholar
• ANDERSON PM, KATSANIS E, SENCER SF, HASZ D, OCHOA AC, BOSTROM B: Depot characteristics and biodistribution of IL-2 liposomes: importance of route. J. Immunother. (1993) 12:19–31.
   Web of Science ®Google Scholar
• ZOLLER M: Unexpected induction of unresponsiveness by vaccination with transformed Salmonella typhimurium. Immunother. (2002) 25(2):162–175.
   Web of Science ®Google Scholar
• ROSENBERG SA, SPIESS PJ, KLEINER DE: Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J. Immunother. (2002) 25:218–225.
   PubMedGoogle Scholar
• CHEN LM, HOBBIES, GALAN JE: Requirement of CDC42 for Salmonella-induced cytoskeletal and nuclear responses. Science (1996) 274:2115–2118.
   PubMed Web of Science ®Google Scholar
• CRISS AK, AHLGREN DM, JOU TS et al.: The GTPase Racl selectively regulates Salmonella invasion at the apical plasma membrane of polarized epithelial cells. J. Cell Sci. (2001) 114:1331–1341.
   PubMed Web of Science ®Google Scholar
• PAWELEK JM, SODI S, CHAKRABORTY AK et al.: Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther. (2002) 9:813–818.
   PubMed Web of Science ®Google Scholar
• LAFRENIERE R, ROSENBERG SA: A novel approach to the generation and identification of hepatic metastases in a murine model. J. Natl Cancer Inst. (1986) 76(2):309–322.
   PubMed Web of Science ®Google Scholar
• WHITTINGTON R, FAULDS D: Interleukin-2: a review of its pharmacologic properties and therapeutic use in patients with cancer. Drugs (1993) 46:446–514.
   PubMed Web of Science ®Google Scholar
• NALUE NA, SHNYRA A, HULATENBY K, LINDBERG AA: Salmonella choleraesuis and Salmonella typhimurium associated with liver cells after intravenous inoculation of rats are localized mainly in Kupffer cells and multiply intracellularly. Infect. Immun. (1992) 60:2758–2768.
   PubMed Web of Science ®Google Scholar
• CONLAN JW, NORTH RJ: Early pathogenesis of infection in the live with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect. Immun. (1992) 60:5164–5171.
   PubMed Web of Science ®Google Scholar
• BRODEUR GM, CASTLEBERRY RP: Neuroblastoma. In: Principles and Practice of Pediatric Oncology 3rd ed. Pizzo PA, Poplack DG (Eds), Lippincott-Raven Publishers, Philadelphia, PA, USA (1997):337.
   Google Scholar
• MILLER RW, YOUNG JL JR, NOVAKOVIC B: Childhood cancer. Cancer (1995) 75(Suppl.):395–405.
   Google Scholar
• MATTHAY KK: Neuroblastoma: a clinicalchallenge and biologic puzzle. CA Cancer J. Clin. (1995) 45:179–192.
   PubMed Web of Science ®Google Scholar
• GARAVENTA A. BELLAGAMBA O, LO PICCOLO MS et al.: 131 I-metaiodobenzylguanidine therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br. J. Cancer (1999) 81:1378–1384.
   Google Scholar
• TEPMONGKOL S, HEYMAN S: 131 I-MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med. Pediatr. Oncol (1999) 32:427–431.
   PubMedGoogle Scholar
• CHEUNG TY, LO PICCOLO MS, COLLINS N, KUSHNER BH, CHEUNG NK: Quantitation of GD2 synthase mRNA by real time reverse transcription-polymerase chain reaction. Cancer (2002) 94:3024–3028.
   Google Scholar
• OZKAYNAK MF, SONDEL PM, KRAILO MD et al.: Phase I study of chimeric human/murine anti-ganglioside gd2 monoclonal antibody with granulocyte-macrophage-colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation. A Children's Oncology Cancer Group Study. J. Clin. Oncol (2000) 18:4077–4085.
   PubMed Web of Science ®Google Scholar
• MATTHAY KK, VILLABLANCA JG, SEEGER RC et al.: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplant, and 13-cis-retinoic acid. N Engl. Med. (1999) 241:1165–1173.
   Google Scholar
• TOSO JF, GILL VJ, HWU P et al.: Phase IStudy of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol (2002) 20(1):142–152.
   PubMed Web of Science ®Google Scholar
• HEIMANN DM, ROSENBERG SA: Continuous intravenous administration of live genetically modified Salmonella typhimurium in patients with metastatic melanoma. J. Immunother. (2003) 26(2):179–180.
   PubMed Web of Science ®Google Scholar
• NEMUNATTIS J, CUNNINGHAM C, SENZER N et al.: Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. (2003) 10:737–744.
   Google Scholar